Melanoma checkpoint inhibitors

Immune checkpoint proteins are among the hottest targets in the cancer immunotherapy space, but many patients do not respond to individual antibodies against the targets. A team of U.S. researchers has found that combining a cocktail of antibodies targeting checkpoint proteins with peptide-based cancer vaccines induced a potent and tumor-specific

T cell response to treat melanoma.¹...